TotalMarketCap

Protalix BioTherapeutics

PLXNYSE IsraelHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$202.638 M

$2.52 -6.51%

Close of 6 Nov 2026

As of 6 Nov 2026, Protalix BioTherapeutics (PLX) has a market capitalization of $202.6M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$52.7M

#2699 by revenue

Earnings

-$6.60M

Loss-making

Shares outstanding

80,571,642

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #92Fate TherapeuticsFATE$225.9M
  2. #93Cabaletta BioCABA$214.5M
  3. #94Protalix BioTherapeuticsPLX$202.6M
  4. #95Artiva BiotherapeuticsARTV$202.4M
  5. #96Palisade BioPALI$202.2M

What if Protalix BioTherapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$350,456.72

Per share 139,347× higher

Bitcoin $1.53T

$18,962.60

Per share 7,540× higher

Apple $5.02T

$62,252.46

Per share 24,752× higher

Or at a round number

$500.0M$1.00B$2.00B$5.00B

Where these numbers come from

Share counts and financials for Protalix BioTherapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.